SEC Form 4 · accession 0001127602-16-064300
LABCORP HOLDINGS INC. · LH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John D Ratliff
Officer — CEO, Covance Drug Development
Period of report
Oct 3, 2016
Accepted (ET)
Oct 5, 2016 · 3:57 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000920148
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF1,F2 | — | Oct 3, 2016 | A | 18,300 | A | — | — | Common Stock | 18,300 | 18,300 | D |
Explanation of responses
- F1Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
- F2The Restricted Stock Units vest in three equal annual installments beginning on 2/9/17.